Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director · 10% owner | January 15, 2019 | January 17, 2019 |
| Sonnet BioTherapeutics Holdings, Inc.SONN · Entity 72220 | Director · Chairman, President and CEO | December 11, 2023 | December 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date January 15, 2019 · Filed January 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,064,553 |
Reported balance
After 2019-01-15 transaction · row 1
1 source rowRow 1 · 2019-01-15 · Purchase · Acquired 8,000 · Balance 7,064,553 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6649 - $0.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 492,753 |
Reported balance
Holding disclosure · report date 2019-01-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 492,753 |
| Common StockSEC Table I · non-derivative | IndirectBy minor child | 39,405 |
Reported balance
Holding disclosure · report date 2019-01-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 39,405 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 86,956 |
Reported balance
Holding disclosure · report date 2019-01-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 86,956 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6649 - $0.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
Sonnet BioTherapeutics Holdings, Inc.
Report date December 11, 2023 · Filed December 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,987 |
Reported balance
After 2023-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-11 · Grant · Acquired 7,554 · Balance 14,987 F1: On December 11, 2023, the Reporting Person was granted 7,554 restricted stock awards, which will be settled in shares of common stock, par value $0.0001. The shares in connection with the restricted stock award become fully vested on January 1, 2025. F2: Includes unvested restricted stock awards. F3: All amounts reflect the Issuer's 1:22 reverse stock split effective as of September 30, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3 |
Reported balance
Holding disclosure · report date 2023-12-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3 F3: All amounts reflect the Issuer's 1:22 reverse stock split effective as of September 30, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Mohan Family Office | 377 |
Reported balance
Holding disclosure · report date 2023-12-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 377 F3: All amounts reflect the Issuer's 1:22 reverse stock split effective as of September 30, 2024. F4: Reporting Person jointly exercises dispositive and voting power over the securities owned by the Mohan Family Office. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 11, 2023, the Reporting Person was granted 7,554 restricted stock awards, which will be settled in shares of common stock, par value $0.0001. The shares in connection with the restricted stock award become fully vested on January 1, 2025.
F2: Includes unvested restricted stock awards.
F3: All amounts reflect the Issuer's 1:22 reverse stock split effective as of September 30, 2024.
F4: Reporting Person jointly exercises dispositive and voting power over the securities owned by the Mohan Family Office.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2023 Filed Dec 6, 2024 02:55 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 7,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-048951 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,987 F1 · shares: On December 11, 2023, the Reporting Person was granted 7,554 restricted stock awards, which will be settled in shares of common stock, par value $0.0001. The shares in connection with the restricted stock award become fully vested on January 1, 2025. F1 · price: On December 11, 2023, the Reporting Person was granted 7,554 restricted stock awards, which will be settled in shares of common stock, par value $0.0001. The shares in connection with the restricted stock award become fully vested on January 1, 2025. F2 · balance_after: Includes unvested restricted stock awards. F3 · balance_after: All amounts reflect the Issuer's 1:22 reverse stock split effective as of September 30, 2024. Read SEC document |
| October 27, 2023 Filed Oct 28, 2023 00:00 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseWarrant to Purchase Common Stock · Derivative | 68,750 | Not disclosed Strike: $1.60 | Not disclosed |
DisclosureSEC source: 0001493152-23-038573 · ownership.xml · derivative · entry 4 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,750 Underlying: Common Stock · 68,750 shares Expires 2028-10-27 F1 · shares: Reporting Person purchased 34,375 shares of common stock and 68,750 warrants to purchase 68,750 shares of common stock pursuant to an underwritten public offering by the Issuer at $1.60 per share and accompanying two warrants. The offering closed on October 27, 2023. F1 · price: Reporting Person purchased 34,375 shares of common stock and 68,750 warrants to purchase 68,750 shares of common stock pursuant to an underwritten public offering by the Issuer at $1.60 per share and accompanying two warrants. The offering closed on October 27, 2023. F3 · balance_after: All amounts reflect the 1:22 reverse stock split effective as of August 31, 2023. Read SEC document |
| October 27, 2023 Filed Oct 28, 2023 00:00 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 34,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-038573 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,526 F1 · shares: Reporting Person purchased 34,375 shares of common stock and 68,750 warrants to purchase 68,750 shares of common stock pursuant to an underwritten public offering by the Issuer at $1.60 per share and accompanying two warrants. The offering closed on October 27, 2023. F1 · price: Reporting Person purchased 34,375 shares of common stock and 68,750 warrants to purchase 68,750 shares of common stock pursuant to an underwritten public offering by the Issuer at $1.60 per share and accompanying two warrants. The offering closed on October 27, 2023. F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: All amounts reflect the 1:22 reverse stock split effective as of August 31, 2023. Read SEC document |
| May 15, 2023 Filed May 15, 2023 21:17 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 371,600 | $0.22 | $82,866.80 |
DisclosureSEC source: 0001493152-23-017528 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,331 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.22 to $0.2274 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:24 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 60,000 | $0.59 | $35,100.00 |
DisclosureSEC source: 0001493152-23-007915 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,731 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.56 to $0.59 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 07, 2023 Filed Feb 17, 2023 21:50 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 73,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-005473 · ownership.xml · nonDerivative · entry 2 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,731 F1 · shares: On December 14, 2022, the Reporting Person was granted 73,561 restricted stock units to be settled in shares of common stock, par value $0.0001. On January 7, 2023, the 73,561 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 73,561 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date. F1 · price: On December 14, 2022, the Reporting Person was granted 73,561 restricted stock units to be settled in shares of common stock, par value $0.0001. On January 7, 2023, the 73,561 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 73,561 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 07, 2023 Filed Feb 17, 2023 21:50 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | Disposition to issuerCommon Stock | 73,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-005473 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,170 F1 · shares: On December 14, 2022, the Reporting Person was granted 73,561 restricted stock units to be settled in shares of common stock, par value $0.0001. On January 7, 2023, the 73,561 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 73,561 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date. F2 · shares: A Form 4 that was filed by the Reporting Person on December 22, 2022, reported a transaction on December 14, 2022, that incorrectly referred to the amount of restricted stock units granted as 74,205. The correct number was 73,561 restricted stock units. In addition, the Form 4 incorrectly included amounts in Column 5 of Table I that did not reflect a 14:1 reverse stock split of the Issuer's common stock, effective September 16, 2022. F1 · price: On December 14, 2022, the Reporting Person was granted 73,561 restricted stock units to be settled in shares of common stock, par value $0.0001. On January 7, 2023, the 73,561 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 73,561 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date. F2 · balance_after: A Form 4 that was filed by the Reporting Person on December 22, 2022, reported a transaction on December 14, 2022, that incorrectly referred to the amount of restricted stock units granted as 74,205. The correct number was 73,561 restricted stock units. In addition, the Form 4 incorrectly included amounts in Column 5 of Table I that did not reflect a 14:1 reverse stock split of the Issuer's common stock, effective September 16, 2022. F3 · balance_after: Includes unvested restricted stock units. Read SEC document |
| December 14, 2022 Filed Dec 22, 2022 21:31 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 74,205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-036319 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748,606 F1 · shares: On December 14, 2022, the Reporting Person was granted 74,205 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024. F1 · price: On December 14, 2022, the Reporting Person was granted 74,205 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| December 15, 2021 Filed Apr 8, 2022 20:30 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 320,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-009482 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,401 F1 · shares: On December 15, 2021, the Reporting Person was granted 320,135 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023. F1 · price: On December 15, 2021, the Reporting Person was granted 320,135 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 22:59 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 28,000 | $1.55 | $43,400.00 |
DisclosureSEC source: 0001493152-21-013938 · ownership.xml · nonDerivative · entry 2 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,266 F1 · balance_after: Includes unvested RSUs. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 22:59 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 4,000 | $1.55 | $6,180.00 |
DisclosureSEC source: 0001493152-21-013938 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,266 F1 · balance_after: Includes unvested RSUs. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 22:20 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 319,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012575 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,266 F1 · shares: On July 2, 2020, the Reporting Person was granted 319,866 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 50% of the restricted stock units on April 2, 2021 and 50% of the restricted stock units on April 2, 2022. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:05 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 2,400 | $4.09 | $9,816.00 |
DisclosureSEC source: 0001493152-20-011086 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Read SEC document |
| April 01, 2020 Filed Apr 4, 2020 01:07 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantWarrant to Purchase Common Stock · Derivative | 4,263 | Not disclosed Strike: $29.32 | Not disclosed |
DisclosureSEC source: 0001493152-20-005846 · ownership.xml · derivative · entry 3 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Mohan Family Office Disclosed balance after: 4,263 Underlying: Common Stock · 4,263 shares Expires 2022-10-14 F3 · price: Prior to the merger, Reporting Person held warrants to purchase 40,000 shares of the common stock of Sonnet Sub at an exercise price of $3.125 per share. Pursuant to the Merger Agreement, these warrants were converted into warrants to purchase 4,263 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $29.32 per share (as adjusted for the stock split). F2 · ownership.nature: Reporting Person jointly exercises dispositive and voting power over the securities owned by the Mohan Family Office. Read SEC document |
| April 01, 2020 Filed Apr 4, 2020 01:07 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 1,591,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-005846 · ownership.xml · nonDerivative · entry 2 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Mohan Family Office Disclosed balance after: 1,591,116 F1 · price: Shares of common stock of the corporation known as Sonnet BioTherapeutics, Inc. ("Sonnet Sub") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger, dated as of October 10, 2019, as amended, by and among the Issuer, Sonnet Sub and Biosub Inc., a Delaware corporation (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Sonnet Sub common stock was exchanged for approximately 0.106572 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Prior to the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 26 shares of Issuer common stock outstanding and the Issuer changed its name to Sonnet BioTherapeutics Holdings, Inc. All share numbers reflect the reverse stock split. F2 · ownership.nature: Reporting Person jointly exercises dispositive and voting power over the securities owned by the Mohan Family Office. Read SEC document |
| April 01, 2020 Filed Apr 4, 2020 01:07 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 7,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-005846 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By child Disclosed balance after: 7,992 F1 · price: Shares of common stock of the corporation known as Sonnet BioTherapeutics, Inc. ("Sonnet Sub") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger, dated as of October 10, 2019, as amended, by and among the Issuer, Sonnet Sub and Biosub Inc., a Delaware corporation (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Sonnet Sub common stock was exchanged for approximately 0.106572 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Prior to the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 26 shares of Issuer common stock outstanding and the Issuer changed its name to Sonnet BioTherapeutics Holdings, Inc. All share numbers reflect the reverse stock split. Read SEC document |
| April 01, 2020 Filed Jun 5, 2020 20:42 UTC Amendment | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 930,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-010670 · ownership.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · Chairman, President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Mohan Family Office Disclosed balance after: 930,705 F1 · price: As reported on a Form 4 filed on April 3, 2020 (the "Original Form"), shares of common stock of Sonnet BioTherapeutics, Inc. ("Sonnet Sub") were converted into shares of the Issuer's common stock pursuant to the Agreement and Plan of Merger, dated as of October 10, 2019, as amended, by and among the Issuer, Sonnet Sub and Biosub Inc. (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Sonnet Sub common stock was exchanged for approximately 0.106572 shares of the Issuer's common stock. This amendment is being filed in order to correct (1) that the Original Form did not have the box for "10% Owner" in Box 5 checked, although the Reporting Person is required to check that box, and (2) the number of shares of the Issuer's common stock that were issued pursuant to the Merger Agreement in exchange for the shares of Sonnet Sub common stock previously held by the Mohan Family Office. F2 · ownership.nature: Reporting Person jointly exercises dispositive and voting power over the securities owned by the Mohan Family Office. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:45 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 8,000 | $0.68 | $5,440.00 |
DisclosureSEC source: 0001209191-19-004233 · doc4.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,064,553 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6649 - $0.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:59 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 114,157 | $0.61 Strike: $0.89 | $69,978.24 |
DisclosureSEC source: 0001209191-18-058307 · doc4.xml · derivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,157 Underlying: Common Stock · 114,157 shares Expires 2028-11-09 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees of $70,000. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:57 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-18-052155 · doc4.xml · derivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-21 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on September 21, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 21:28 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 62,569 | $1.16 | $72,580.04 |
DisclosureSEC source: 0001209191-18-002466 · doc4.xml · nonDerivative · entry 2 Mohan Pankaj · CIK 0001664386 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,056,553 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.13 - $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. F3 · balance_after: Includes 202,898 shares of the Issuer's common stock that vested on 12/31/2017. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:28 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 52,108 | $1.18 | $61,487.44 |
DisclosureSEC source: 0001209191-18-002466 · doc4.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,119,122 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.16 - $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 202,898 shares of the Issuer's common stock that vested on 12/31/2017. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 00:55 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 83,608 | $1.14 | $95,313.12 |
DisclosureSEC source: 0001209191-17-066693 · doc4.xml · nonDerivative · entry 2 Mohan Pankaj · CIK 0001664386 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,171,230 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 - $1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. F3 · balance_after: Includes 202,898 shares of the Issuer's common stock subject to RSUs that will vest on 12/31/2017, subject to continued service through such date. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 00:55 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 20,523 | $1.17 | $24,011.91 |
DisclosureSEC source: 0001209191-17-066693 · doc4.xml · nonDerivative · entry 1 Mohan Pankaj · CIK 0001664386 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,254,838 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. F3 · balance_after: Includes 202,898 shares of the Issuer's common stock subject to RSUs that will vest on 12/31/2017, subject to continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.